Ironwood Pharmaceuticals reported total revenues of $352.6 million for the nine months ended September 30, 2026, a significant increase from $248.4 million in the prior year period. Net income for the same period rose to $151.9 million, driven by higher collaborative arrangement revenue and a reduction in total costs and expenses.
Ironwood Pharmaceuticals reported Q3 2026 total revenue of $133 million and GAAP net income of $60 million, driven by strong LINZESS U.S. net sales of $325 million. Due to strong performance, the company raised its full-year 2026 LINZESS U.S. net sales guidance to $1.20 - $1.25 billion and total revenue guidance to $485 - $510 million.
Counterparty
AbbVie Inc.
Term
Q3 2026
“Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cash flows. We believe LINZESS is on its way to returning to blockbuster status for 2026 with year-to-date U.S. net sales already surpassing total 2025 U.S. net sales, primarily driven by improved net price and mid-single-digit prescription demand growth.”
Tom McCourt, Ironwood Chief Executive Officer
“In addition to driving strong financial performance, we are ramping up the STARS-2 confirmatory Phase 3 trial of apraglutide in people living with short bowel syndrome with intestinal failure. As we continue to add trial sites in the U.S., all of the planned clinical trial applications have been submitted to international health authorities and are now under review or already approved.”
Ironwood Pharmaceuticals appointed Tammi Gaskins, currently Senior Vice President and Chief Commercial Officer, as Chief Executive Officer and a director, effective January 1, 2027. She succeeds Thomas McCourt, who will retire as CEO on December 31, 2026, after 17 years with the company but will remain on the Board of Directors. Gaskins will receive an annual base salary of $775,000 and $4 million in target equity grant value as part of her new role.